NHS to Offer Life-Changing Cystic Fibrosis Drug
Alyftrek Recommended by NICE for Cystic Fibrosis, Expanding Treatment Options in the UK
Table of Contents
London, UK – [Date of Publication] – The National Institute for Health and Care Excellence (NICE) has issued a positive suggestion for Alyftrek (ivacaftor/tezacaftor/elexacaftor), a new triple combination therapy for cystic fibrosis (CF). This landmark decision, announced in April, significantly expands treatment access for individuals with the genetic disorder, offering a once-daily option to existing therapies and extending coverage to those with rarer forms of the condition.
NICE Approves Alyftrek as a New Standard of Care
NICE’s recommendation follows a rapid assessment that compared Alyftrek with Vertex Pharmaceuticals’ previously approved triple therapy, Kaftrio (elexacaftor/tezacaftor/ivacaftor). Evidence presented indicates that Alyftrek demonstrates comparable efficacy to Kaftrio in improving lung function, promoting growth and weight gain, and reducing the frequency of lung infections. A key advantage highlighted by NICE is Alyftrek’s once-daily dosing regimen, which contrasts with Kaftrio’s twice-daily administration.
The health technology assessment body has advised that Alyftrek can be offered to patients who are unable to take Kaftrio, and also serving as an alternative for those already receiving kaftrio. This dual recommendation aims to optimize treatment pathways and patient convenience.
Alyftrek is available in two dose formulations:
Vnz 10 mg / Tez 50 mg / Diva 125 mg (84-tablet pack)
Vnz 4 mg / Tez 20 mg / Diva 50 mg (56-tablet pack)
Both pack sizes carry a list price of £16,110, excluding VAT. The NICE recommendation is contingent upon Vertex Pharmaceuticals providing the drug under the terms of a confidential commercial arrangement. Clinicians are encouraged to prioritize the most cost-effective suitable treatment, taking into account dosage, administration costs, and the negotiated commercial terms.
David Ramsden, chief executive of the Cystic Fibrosis Trust, welcomed the decision, describing it as “a positive step in the journey to better treatments for more people with cystic fibrosis.” Similar positive announcements are anticipated in Scotland, Wales, and Northern Ireland, according to the trust.
Alyftrek’s Potential Impact on Patient Lives
The introduction of Alyftrek represents a significant advancement in CF care. Its once-daily dosing offers a more convenient treatment schedule, potentially improving adherence and integrating more seamlessly into patients’ daily routines. For individuals managing a chronic condition like cystic fibrosis, such improvements in treatment convenience can have a significant impact on quality of life, reducing the burden of medication management and allowing for greater freedom and independence.
NHS Expands access Beyond NICE Scope with Commercial Deal
In a move that further broadens access to advanced CF therapies, NHS England (NHSE) has announced a commercial deal with Vertex Pharmaceuticals to extend the availability of Alyftrek beyond the patient population evaluated by NICE. This agreement will make the triple combination therapy accessible to children and adults with rare forms of cystic fibrosis who were previously ineligible for modulator therapy.
NHSE estimates that this expansion will make approximately 95% of individuals with cystic fibrosis in england eligible for modulator therapy, a significant increase in access to potentially life-changing treatments.
John Stewart, NHSE’s director for specialised commissioning, hailed the development as “a major leap forward.” He emphasized the transformative impact of these therapies, stating, “For those living with the rarest forms of the condition, this represents the very first time they will be able to access this new standard of care that has been so transformative for many.”
Stewart further noted the potential for once-daily treatment at home to reduce hospital visits and empower children with CF to lead more active and independent lives. This proactive expansion by NHSE underscores a commitment to ensuring that the benefits of cutting-edge CF treatments reach the widest possible patient group.
Understanding Cystic Fibrosis and Modulator Therapies
Cystic fibrosis is a progressive, genetic disease that affects the lungs and other organs. It is caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene, which leads to the production of thick, sticky mucus that can clog the airways, leading to chronic lung infections and progressive lung damage.
Modulator therapies, such as Kaftrio and now Alyftrek, work by targeting the underlying defect in the CFTR protein. These therapies are designed to help the CFTR protein function more effectively, thereby reducing the buildup of mucus and improving lung function